Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.6 billion for the second quarter of 2023, which was up 5% year-over-year.
Net income attributable to Gilead was $1 billion, or $0.83 per share, compared to $1.1 billion, or $0.91 per share, last year. Adjusted EPS was $1.34.
For the full year of 2023, GAAP EPS is expected to be $4.50-4.85 while adjusted EPS is estimated to be $6.45-6.80.
Prior performance
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was
